Highest-materiality recent filing
Precipio Q2 2026 revenue record $7.0M, positive adjusted EBITDA $0.4M
Revenue $7.0M, up 22% YoY from $5.7M; pathology $6.1M, product $0.9M.
Precipio schedules Q2-2026 shareholder update call for August 17, 2026
Call on August 17, 2026 at 5:00 PM ET; includes moderated live Q&A session.
Precipio shareholders elect three Class II directors and ratify auditor at annual meeting
Richard Sandberg, Christina Valauri, and Jeffrey Cossman elected as Class II directors for terms expiring 2029.
Precipio schedules Q1 2026 shareholder update call for May 18 with live Q&A
Shareholder update call will be held on May 18, 2026, at 5:00 PM ET.
Precipio reports 30% revenue growth to $24M in 2025; positive EBITDA and cash flow
Revenue grew 30% YoY to $24.0M in FY2025; Q4 revenue up 23% YoY to $6.7M.
Precipio adjusts executive salaries, grants performance stock options with $40 VWAP trigger
Ilan Danieli (CEO) salary $350k, bonus $200k; effective Jan 1, 2026.
Precipio schedules Q3-2025 shareholder update call for Nov 17, 2025
Call scheduled for November 17, 2025 at 5:00 PM ET.
Precipio terminates ATM facility with AGP, citing improved cash flow and stronger balance sheet
Terminated at-the-market (ATM) sales agreement with A.G.P. effective September 2, 2025.
Precipio updates investor presentation; no material new financial data
Updated investor presentation posted Aug 18, 2025; supersedes version from June 13, 2022.
Precipio schedules Q2-2025 shareholder update call for August 14, 2025
Call to be held August 14, 2025 at 5:00 PM ET to discuss core business updates.
Precipio stockholders elect Danieli and Cohen as Class I directors, ratify CBIZ as auditor
Elected Ilan Danieli with 387,281 votes for, 11,643 withheld; David S. Cohen with 385,237 votes for, 13,687 withheld.
Precipio Q1 revenue up 43% to $4.9M; adjusted EBITDA loss narrows 92% to $108K
Revenue $4.9M, +43% YoY; overall gross margin improved to 43% from 27%.
Precipio schedules Q1-2025 shareholder update call for May 15, 2025
Call on May 15, 2025 at 5:00 PM ET; management will update on all core businesses.
Precipio's auditor Marcum resigns after CBIZ acquisition; CBIZ appointed
Marcum resigned on April 9, 2025 as independent auditor due to CBIZ acquiring its attest business.
Precipio schedules Q4 and year-end 2024 shareholder update call for March 31
Shareholder update call scheduled for March 31, 2025 at 5:00 PM ET.
Precipio grants 34,000 performance-based options to four officers with 5x stock price vesting target
Compensation Committee granted 34,000 options to CEO Ilan Danieli (8,000), Ayman Mohamed (6,000), Ahmed Zaki Sabet (6,000), and Matthew Gage (4,000).
Precipio grants senior mgmt performance options vesting at $30.30/share (5x exercise price of $6.06)
Options granted Jan 14, 2025; vest only when 10-day VWAP exceeds $30.30 per share.
Precipio schedules Q3 2024 investor call for Nov 18; 10-Q filed
Shareholder update call on November 18, 2024 at 5:00 PM ET to discuss Q3-2024 10-Q.
Precipio reprices ~177,000 options to $6.56 for employees and directors
Board approved repricing of options granted before Dec 31, 2022 with exercise prices above $6.56 to $6.56 (Aug 30 close).
Precipio schedules Q2-2024 shareholder update call for August 19
Call to be held August 19, 2024 at 5:00 PM ET; dial 844-695-5519.
Precipio stockholders elect LaPorte and Andrews as Class III directors at annual meeting
Kathleen D. LaPorte and Ron A. Andrews elected as Class III directors for terms expiring 2027.
Precipio secures $500K loan facility due to Change Healthcare cyberattack cash-flow delay
Loan agreement with Altbanq Lending LLC for $250K initial draw; up to $500K total available.
Precipio terminates its factoring agreement with Culain Capital Funding
Terminated Factoring Agreement with Culain Capital Funding, dated March 23, 2023, effective April 30, 2024.
Precipio schedules year-end 2023 shareholder update call for April 1
Shareholder update call on April 1, 2024 at 5:00 PM ET; dial-in 844-695-5519.
Precipio appoints Christina Valauri to board; Douglas Fisher steps down as director
Christina Valauri appointed to board effective Jan 1, 2024 as class II director; term expires at 2026 annual meeting.
Precipio achieves two of three 2023 goals; revenue up ~50% YoY, cash burn cut 60%
Pathology division hit $14M annualized revenue in Q3, meeting target #1; product target lowered to $6M.
Precipio to host Q3-2023 shareholder update call on Nov 20
Call scheduled for November 20, 2023 at 5:00 PM ET.
Nasdaq confirmed compliance on Oct 6, 2023, based on closing bid prices from Sep 22 to Oct 5, 2023.
Precipio effects 1-for-20 reverse stock split to regain Nasdaq compliance
Reverse split 1-for-20 effective Sept 21, 2023; split-adjusted trading starts Sept 22.
Precipio announces Q2-2023 shareholder update conference call for Aug 17
Conference call scheduled for August 17, 2023 at 5:00 PM ET; dial-in: 844-695-5519.
Precipio shareholders elect directors, ratify auditor, authorize reverse stock split up to 1:30
Elected Richard Sandberg, Douglas Fisher, Jeffrey Cossman as Class II directors (terms expiring 2026); each received >5.2M votes for.
Precipio raises $2M in registered direct offering and private placement of common stock and warrants
Issued 4,125,000 shares at $0.45/share and pre-funded warrants for 319,445 shares, raising ~$2M gross.
Precipio announces Q1-2023 shareholder update call for May 17
Call to be held May 17, 2023 at 5:00 PM EST; dial-in 844-695-5519.
Precipio granted 180-day extension from Nasdaq to regain $1.00 minimum bid compliance
Nasdaq granted extension until October 23, 2023 to meet $1.00 closing bid for 10 consecutive days.
Precipio enters ATM equity offering agreement for up to $5.8M with A.G.P.
Entered Sales Agreement with A.G.P./Alliance Global Partners for at-the-market offering of common stock up to $5.8M.
Precipio announces Q4-2022 and year-end shareholder update call for April 3, 2023
Call scheduled for Monday, April 3, 2023 at 5:00 PM EST.
Chairman adopts 10b5-1 plan to buy up to $40k of Precipio stock
Chairman Richard Sandberg adopted a Rule 10b5-1 stock purchase plan on Nov 18, 2022.
Precipio schedules Q3 2022 shareholder update call for Nov 14, 2022
Call to be held Monday, November 14, 2022 at 5:00 PM ET.
Precipio receives Nasdaq notice of non-compliance with $1.00 bid price rule
Closing bid price per share below $1.00 for 30 consecutive business days as of October 28, 2022.
Director David Seth Cohen adopts 10b5-1 plan to sell up to 200,000 shares
Plan adopted on Sept 15, 2022, to sell up to 200,000 shares of common stock.
CEO Ilan Danieli adopts 10b5-1 trading plan for quarterly purchases and price-based sales
CEO Ilan Danieli adopted a 10b5-1 plan on Sept 16, 2022.
Precipio schedules Q2-2022 shareholder update call for Aug 15, 2022
Call on Monday, August 15, 2022 at 5:00 PM EST; dial-in 844-695-5519 (international 412-902-6760).
Precipio enters distribution agreement with Fisher Healthcare for HemeScreen assays
Precipio (PRPO) entered a distribution agreement with Fisher Healthcare (Thermo Fisher Scientific) for HemeScreen assays.
Precipio stockholders re-elect Ilan Danieli and David Cohen as directors; ratify Marcum LLP
Class I directors Ilan Danieli and David Cohen re-elected with votes for 5,307,114 and 5,216,439 respectively; term expires 2025.
Precipio annual meeting adjourned due to insufficient quorum; rescheduled to July 5
Meeting adjourned because only ~49% of stockholders had voted, below the 50% quorum required.
Precipio posts updated corporate presentation; no specific financial updates disclosed.
Investor presentation outlines Precipio's cancer diagnostics solutions business and strategy.
Precipio schedules Q4-2021 and year-end shareholder update call for April 4, 2022
Shareholder update call will be held on Monday, April 4, 2022 at 5:00 PM EST.
Precipio CFO Carl Iberger retires; Matthew Gage appointed Interim CFO effective March 21, 2022
Carl Iberger, age 69, retired as CFO effective March 21, 2022, citing personal family reasons.
Precipio reports preliminary 2021 revenue of $8.9M, up 45% YoY; Q4 revenue $2.4M up 25%
Preliminary unaudited 2021 revenue $8.9M, up $2.8M (45%) from 2020.
Precipio schedules Q3-2021 shareholder update call for November 15, 2021
Conference call on Monday, November 15, 2021 at 5:00 PM EST.
the Board appointed Ms. Christina Valauri to fill the vacancy left by Mr. Fisher’s resignation and to serve as a class II director of the Company
the Board of Directors (the “Board”) of Precipio, Inc. (the “Company”) accepted the resignation of Douglas Fisher as a member of the Board
Management together with the Board of Directors of the Company has promoted and appointed Matthew Gage (age 55), currently the Company’s Director of Financial Reporting and Analysis, as the Company’s Interim Chief Financial Officer effective March 21, 2022.
announced the retirement of its Chief Financial Officer, Carl Iberger, (age 69) effective immediately due to personal family reasons.
Max materiality 0.85 · Median 0.30 · Most common event other_material